文献速递免疫规划卫生政策与健康促进传染病防控与疫情报告

巴西成人破伤风-白喉-无细胞百日咳疫苗普遍接种的成本效果分析

Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil.
PubMed 文献 · Vaccine · 2019-10-21

巴西2011-2014年百日咳暴发后,本研究采用动态模型从卫生系统视角评估20岁成人单剂Tdap普遍接种与当前仅孕妇接种策略的成本效果,时间跨度10年,贴现率5%。结果显示,在疫苗有效性82.6%、覆盖率40%、每剂7.01美元并假设群体保护下,普遍接种可避免167例婴儿死亡、挽救12,325生命年,总成本105,495,891.61美元,ICER为8,459.13美元/生命年,结论认为该干预不具有成本效果。

要点

  • 20岁成人单剂Tdap普遍接种相比当前策略,ICER为8,459.13美元/生命年。
  • 模型假设疫苗有效性82.6%、覆盖率40%、每剂7.01美元,可避免167例婴儿死亡。
  • 结果对疾病发病率高度敏感。

核心结论

  • 在巴西,20岁成人单剂Tdap普遍接种相比当前仅孕妇接种策略,不具有成本效果。

研究设计与样本

  • 经济评价采用动态模型,比较20岁成人单剂Tdap普遍接种与当前实践(仅孕妇接种百日咳疫苗)两种策略。
  • 采用卫生系统视角,时间跨度10年,成本和收益贴现率5%。
  • 疫苗有效性来自基于人群的观察性研究,流行病学、资源利用和成本估计来自巴西健康信息系统。
  • 主要结局为每挽救生命年成本(LYS),基于2015年巴西出生时预期寿命,并进行单因素和多因素敏感性分析。

主要发现

  • 在疫苗有效性82.6%、覆盖率40%、每剂7.01美元并假设群体保护下,成人普遍接种可避免167例婴儿百日咳死亡,挽救12,325生命年。
  • 从卫生系统视角,总成本为105,495,891.61美元,ICER为8,459.13美元/生命年。
  • 结果对疾病发病率高度敏感。

关键数值与推荐

  • 疫苗有效性82.6%,覆盖率40%,每剂价格7.01美元,贴现率5%,时间跨度10年。
  • 避免167例婴儿死亡,挽救12,325生命年,总成本105,495,891.61美元,ICER为8,459.13美元/生命年。

临床怎么用

  • 该分析结果提示,在巴西国家免疫规划中引入20岁成人单剂Tdap普遍接种可能不具有成本效果。
  • 决策者需结合当地疾病发病率等不确定性因素综合考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A pertussis outbreak occurred in Brazil from 2011 to 2014, despite high coverage of whole-cell pertussis containing vaccines in early childhood. Infants were the most affected. This study aimed to evaluate the cost-effectiveness of introducing universal adult vaccination with Tdap into the National Immunization Program in Brazil. METHODS: Economic evaluation using a dynamic model to compare two strategies: (1) universal vaccination with single dose of Tdap at 20 years of age and (2) current practice (only pregnant women pertussis vaccination). The health system perspective was adopted. Temporal horizon was 10 years. Discount rate of 5% was applied to costs and benefits. Vaccine effectiveness (VE) was obtained from a population-based observational study. Epidemiological, resource utilization and cost estimates were obtained from the Brazilian Health Information Systems. The primary outcome was cost per life year saved (LYS), based on life expectancy at birth in Brazil in 2015. Univariate and multivariate sensitivity analysis were performed. RESULTS: Adult vaccination with VE of 82.6% and coverage of 40%, at price of US$7.01 per dose, and assuming herd protection would avoid 167 infant deaths by pertussis, saving 12,325 years of life and costing a total of US$105495891.61, from the health system perspective. The universal immunization would result in ICER of US$8459.13. The results were highly sensitive to disease incidence. CONCLUSIONS: The results suggest that universal adult vaccination with Tdap would not be a cost-effective intervention for preventing pertussis cases and deaths in infants in Brazil.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fernandes EG, Sartori AMC, de Soárez PC, et al. Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil. Vaccine. 2019. PMID: 31648911. doi:10.1016/j.vaccine.2019.09.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。